Table 3.
Differences of basic lymphocyte subtypes and plasmablasts between patients: with positive COVID-19 test—group A, control group (HC)—group B and group with other virus infections with negative COVID-19 test—group C. Data expressed as median (Q1–Q3).
| Lymphocyte Subset (%) [Median (Q1–Q3)] |
A. COVID-19(+) n = 20 |
B. HC n = 20 |
C. COVID-19(−) Viruses n = 20 |
* p < 0.05 A-B-C Anova |
* p < 0.05 in Group Post Hoc |
|---|---|---|---|---|---|
| Lymphocytes subsets: (% of all cells) | |||||
| Lymphocytes [%] [103/µL] |
32.6 (21.1–49.3) 0.98 (0.76–2.99) |
39.7 (34.2–44.7) 2.16 (1.75–2.73) |
36.9 (28.7–45.5) 2.25 (1.64–3.08) |
* 0.0350 |
A-B, A-C |
| Lymphocytes T [%] [103/µL] |
24.3 (13.9–37.5) 0.65 (0.57–2.24) |
29.6 (25.6–35.0) 1.73 (1.39–2.13) |
28.1 (23.6–34.3) 1.88 (1.25–2.40) |
- - |
|
| Lymphocytes T CD4 [%] [103/µL] |
13.3 (6.3–23.1) 0.48 (0.26–1.11) |
18.8 (16.1–20.7) 1.04 (0.84–1.27) |
16.5 (12.8–26.0) 1.08 (0.70–1.38) |
- - |
|
| Lymphocytes T CD8 [%] [103/µL] |
9.9 (4.2–12.6) 0.33 (0.16–0.86) |
11.7 (8.1–14.4) 0.70 (0.50–0.90) |
13.5 (10.1–7.4) 0.57 (0.45–0.85) |
- - |
|
| CD4/CD8 | 1.3 (1.0–3.5) | 1.4 (1.3–2.1) | 1.5 (1.3–0.7) | - | |
| Lymphocytes B [%] [103/µL] |
2.0 (1.4–4.7) 0.13 (0.03–0.18) |
3.3 (2.5–4.1) 0.23 (0.12–0.28) |
2.8 (2.0–4.2) 0.20 (0.12–0.28) |
- - |
|
| NK cells [%] [103/µL] |
5.0 (4.1–9.1) 0.18 (0.10–0.40) |
3.4 (2.5–5.6) 0.21 (0.13–0.38) |
5.0 (2.5–6.5) 0.25 (0.14–0.44) |
- - |
|
|
Plasmablasts (% of B CD19+ cells) |
8.8 (6.1–26.5) | 2.7 (1.8–3.5) | 11.1 (2.2–26.2) | * 0.0001 | * A-B * B-C |
Abbreviations: HC healthy control; RE-LYMP, reactive lymphocytes, * p < 0.05 statistically significant.